Axoltis pharma is a biopharmaceutical company dedicated to develop first-in-class disease-modifying drugs to treat patients with neurodegenerative or traumatic neurological disorders with high unmet medical needs. Our innovative approach: combining Preventative, Neuroprotective, Regenerative & Remodeling properties in a single drug, as the key to cure complex neurological disorders. Our products are first-in-class multifunctional peptides with high potential in many CNS disorders.
Location: France
Employees: 11-50
Total raised: $21.05M
Investors 1
| Date | Name | Website |
| - | Angelor | angelor.bi... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 02.12.2025 | Series A | $21.05M | - |
Mentions in press and media 5
| Date | Title | Description |
| 17.02.2026 | Irish Biotech Aerska Secures $39M for Brain Shuttle RNA Medicines | Aerska, an Irish biotech firm, secured a $39 million Series A funding round. This significant investment will propel its proprietary brain shuttle technology. The platform targets challenging neurological diseases. It delivers RNA medicines... |
| 10.02.2026 | Irish BioTech startup Aerska raises €32 million to “enable our loved ones to live longer” | Dublin’s Aerska, a BioTech company using brain shuttle technology to develop RNA medicines for CNS diseases, today announced the close of a €32 million ($39 million) Series A financing to improve delivery of RNAi interference (RNAi) therape... |
| 02.12.2025 | Axoltis Pharma Raises €18M in Series A Funding | Axoltis Pharma, a Clermont-Ferrand, France-based biotech company dedicated to developing therapeutic solutions for neurodegenerative diseases, raised €18M in Series A funding. The round was led by Norfoalk, the Fonds Régional Avenir Industr... |
| 02.12.2025 | New approaches to ALS, Alzheimer’s and Parkinson’s receive support as Axoltis Pharma secures €18 million | Axoltis Pharma, a French BioTech company dedicated to developing novel therapeutic solutions for neurodegenerative diseases, today announces the closing of a €18 million ($20.9 million) Series A funding round in order to develop its lead dr... |
| - | Axoltis pharma | “Axoltis – Innovative drugs for neurologicals disorders” |